13-cis-retinoic acid (NSC 122758) in the treatment of children with metastatic neuroblastoma unresponsive to conventional chemotherapy: report from the Childrens Cancer Study Group. 1992

J Z Finklestein, and M D Krailo, and C Lenarsky, and S Ladisch, and G K Blair, and C P Reynolds, and A L Sitarz, and G D Hammond
Harbor/UCLA Medical Center, Torrance.

The Childrens Cancer Study Group evaluated daily oral 13-cis-retinoic acid to determine its therapeutic efficacy in 28 children with advanced neuroblastoma refractory to conventional therapy. Cheilitis and fissured lips were the most common side effects; however, fewer than 50% of the patients experienced any toxicity. Two of twenty-two evaluable children demonstrated positive response to therapy. In one case, a child received the drug for 11 months. Seventeen patients demonstrated progressive disease within 28 days of the start of treatment. Three other patients with stable disease, or removed from study at day 28, were considered nonresponsive. Our data demonstrate that, when given as a single daily oral dose of 100 mg/m2, 13-cis-retinoic acid does not have significant activity in children with advanced neuroblastoma.

UI MeSH Term Description Entries
D007223 Infant A child between 1 and 23 months of age. Infants
D009447 Neuroblastoma A common neoplasm of early childhood arising from neural crest cells in the sympathetic nervous system, and characterized by diverse clinical behavior, ranging from spontaneous remission to rapid metastatic progression and death. This tumor is the most common intraabdominal malignancy of childhood, but it may also arise from thorax, neck, or rarely occur in the central nervous system. Histologic features include uniform round cells with hyperchromatic nuclei arranged in nests and separated by fibrovascular septa. Neuroblastomas may be associated with the opsoclonus-myoclonus syndrome. (From DeVita et al., Cancer: Principles and Practice of Oncology, 5th ed, pp2099-2101; Curr Opin Oncol 1998 Jan;10(1):43-51) Neuroblastomas
D012074 Remission Induction Therapeutic act or process that initiates a response to a complete or partial remission level. Induction of Remission,Induction, Remission,Inductions, Remission,Remission Inductions
D002613 Cheilitis Inflammation of the lips. It is of various etiologies and degrees of pathology. Cheilitides
D002648 Child A person 6 to 12 years of age. An individual 2 to 5 years old is CHILD, PRESCHOOL. Children
D002675 Child, Preschool A child between the ages of 2 and 5. Children, Preschool,Preschool Child,Preschool Children
D003131 Combined Modality Therapy The treatment of a disease or condition by several different means simultaneously or sequentially. Chemoimmunotherapy, RADIOIMMUNOTHERAPY, chemoradiotherapy, cryochemotherapy, and SALVAGE THERAPY are seen most frequently, but their combinations with each other and surgery are also used. Multimodal Treatment,Therapy, Combined Modality,Combined Modality Therapies,Modality Therapies, Combined,Modality Therapy, Combined,Multimodal Treatments,Therapies, Combined Modality,Treatment, Multimodal,Treatments, Multimodal
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D000293 Adolescent A person 13 to 18 years of age. Adolescence,Youth,Adolescents,Adolescents, Female,Adolescents, Male,Teenagers,Teens,Adolescent, Female,Adolescent, Male,Female Adolescent,Female Adolescents,Male Adolescent,Male Adolescents,Teen,Teenager,Youths
D015474 Isotretinoin A topical dermatologic agent that is used in the treatment of ACNE VULGARIS and several other skin diseases. The drug has teratogenic and other adverse effects. 13-cis-Retinoic Acid,Accutane,Isotretinoin Zinc Salt, 13-cis-Isomer,Ro 4-3780,Roaccutane,13 cis Retinoic Acid,Isotretinoin Zinc Salt, 13 cis Isomer,Ro 4 3780,Ro 43780

Related Publications

J Z Finklestein, and M D Krailo, and C Lenarsky, and S Ladisch, and G K Blair, and C P Reynolds, and A L Sitarz, and G D Hammond
January 1979, Medical and pediatric oncology,
J Z Finklestein, and M D Krailo, and C Lenarsky, and S Ladisch, and G K Blair, and C P Reynolds, and A L Sitarz, and G D Hammond
October 1999, The New England journal of medicine,
J Z Finklestein, and M D Krailo, and C Lenarsky, and S Ladisch, and G K Blair, and C P Reynolds, and A L Sitarz, and G D Hammond
December 2014, British journal of pharmacology,
J Z Finklestein, and M D Krailo, and C Lenarsky, and S Ladisch, and G K Blair, and C P Reynolds, and A L Sitarz, and G D Hammond
February 2007, British journal of cancer,
J Z Finklestein, and M D Krailo, and C Lenarsky, and S Ladisch, and G K Blair, and C P Reynolds, and A L Sitarz, and G D Hammond
January 1985, Journal of neuro-oncology,
J Z Finklestein, and M D Krailo, and C Lenarsky, and S Ladisch, and G K Blair, and C P Reynolds, and A L Sitarz, and G D Hammond
January 2007, Therapie,
J Z Finklestein, and M D Krailo, and C Lenarsky, and S Ladisch, and G K Blair, and C P Reynolds, and A L Sitarz, and G D Hammond
January 2013, Clinical cancer research : an official journal of the American Association for Cancer Research,
J Z Finklestein, and M D Krailo, and C Lenarsky, and S Ladisch, and G K Blair, and C P Reynolds, and A L Sitarz, and G D Hammond
April 2008, Pediatrics international : official journal of the Japan Pediatric Society,
J Z Finklestein, and M D Krailo, and C Lenarsky, and S Ladisch, and G K Blair, and C P Reynolds, and A L Sitarz, and G D Hammond
April 2009, Journal of pediatric hematology/oncology,
J Z Finklestein, and M D Krailo, and C Lenarsky, and S Ladisch, and G K Blair, and C P Reynolds, and A L Sitarz, and G D Hammond
January 1994, Progress in clinical and biological research,
Copied contents to your clipboard!